PROTAMINE SULFATE

Post-LOE

Hikma

ANDAINTRAVENOUSSOLUTION

Approved

Nov 1986

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PROTAMINE SULFATE by Hikma is clinical pharmacology: when administered alone, protamine has an anticoagulant effect. Approved for the treatment of heparin overdosage. First approved in 1986.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY: When administered alone, protamine has an anticoagulant effect. However, when it is given in the presence of heparin (which is strongly acidic), a stable salt is formed and the anticoagulant activity of both drugs is lost. Protamine sulfate has a rapid onset of action.…

Indications (1)

the treatment of heparin overdosage

Company

Worked on PROTAMINE SULFATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.